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ABSTRACT: Methionyl-tRNA synthetase (MetRS) is a chemi-
cally validated drug target in kinetoplastid parasites Trypanosoma
brucei and Leishmania donovani. To date, all kinetoplastid MetRS
inhibitors described bind in a similar way to an expanded
methionine pocket and an adjacent, auxiliary pocket. In the
current study, we have identified a structurally novel class of
inhibitors containing a 4,6-diamino-substituted pyrazolopyrimidine
core (the MetRS02 series). Crystallographic studies revealed that
MetRS02 compounds bind to an allosteric pocket in L. major
MetRS not previously described, and enzymatic studies demon-
strated a noncompetitive mode of inhibition. Homology modeling of the Trypanosoma cruzi MetRS enzyme revealed key differences
in the allosteric pocket between the T. cruzi and Leishmania enzymes. These provide a likely explanation for the lower MetRS02
potencies that we observed for the T. cruzi enzyme compared to the Leishmania enzyme. The identification of a new series of MetRS
inhibitors and the discovery of a new binding site in kinetoplastid MetRS enzymes provide a novel strategy in the search for new
therapeutics for kinetoplastid diseases.
KEYWORDS: Leishmania, kinetoplastid, methionyl-tRNA synthetase, drug discovery, allosteric, inhibitor
Methionyl-tRNA synthetase (MetRS; EC 6.1.1.10) is amember of the aminoacyl-tRNA synthetase family of
enzymes and plays a fundamental role in protein synthesis by
catalyzing the production of methionyl-tRNA, a key molecule
that binds AUG codons at the ribosome during translation,
allowing the incorporation of methionine into nascent proteins.
The production of methionyl-tRNA is a two-step procedure,
with the first step resulting in the production of a methionyl-
AMP intermediate and pyrophosphate and the second step
producing methionyl-tRNA and AMP.
Due to the pivotal role that MetRS plays in protein synthesis,
this enzyme has been described as a validated drug target in
many disease-relevant organisms,1−6 and several drug discovery
programs against this target have been initiated.1,2,4,7−14 In
particular, MetRS has been successfully exploited as a target in
Gram-positive bacteria with MetRS inhibitor CRS3123 having
recently completed two phase I clinical trials for the treatment of
Clostridium dif f icile infections (clinical trial identifiers
NCT01551004 and NCT02106338).13,15
In addition to Gram-positive bacteria, MetRS has also been
validated as a drug target in kinetoplastid parasites.5,6,16−18
Trypanosoma brucei subspecies, Leishmania species, and Trypano-
soma cruzi are the causative agents of human African
trypanosomiasis, leishmaniasis, and Chagas disease, respectively.
These neglected tropical diseases affect millions of people,19 and
new treatment options are urgently required due to limitations
of the currently available therapies: high cost, host toxicity, and
emerging drug resistance.20 Consequently, identifying inhibitors
of kinetoplastid MetRS provides a rational drug discovery
strategy for these devastating diseases.
Previous high-throughput screening and drug discovery
efforts have successfully identified potent inhibitors of both T.
brucei MetRS (TbMetRS) and L. donovani MetRS
(LdMetRS),5,6,16−18,21−23 with well-characterized binding sites
and modes of inhibition defined.6,16−18,21,22,24,25 Interestingly,
there is little chemical diversity found in the kinetoplastid
MetRS inhibitors identified to date, with hit compounds sharing
the same aminoquinolone core scaffold (compound series
MetRS01) and binding to two well-characterized sites of the
enzyme (the methionine pocket and an adjacent, auxiliary
pocket)6,21,22,24,25 that are highly conserved across all
kinetoplastid MetRS enzymes.26
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Despite previous detailed characterization of the LdMetRS
aminoquinolone (MetRS01) inhibitor, DDD806905 (Figure
1A), this compound failed to translate into in vivo efficacy in a
leishmaniasis animal model.6 This was shown to be due to a
combination of reasons: high protein binding, ionization of the
compound, and accumulation of the compound in acidic
compartments. Although DDD806905 failed to show in vivo
efficacy, LdMetRS remains an attractive Leishmania drug target
requiring novel chemical start points.
In the current study, we describe the identification and
characterization of a new series of LdMetRS inhibitors that
target a previously undefined, allosteric binding site in the
enzyme. Further investigation of compounds from this chemical
series shows that they have different inhibitory profiles against
LdMetRS and the T. cruzi MetRS enzyme (TcMetRS), with
crystallography and computational modeling used to rationalize
these differences.
■ RESULTS
LdMetRS: Hit Discovery. In order to identify novel
chemical starting points for an LdMetRS drug discovery
program, a new compound library screen was performed. All
known MetRS inhibitors identified to date are competitive with
respect to methionine; therefore, in an effort to identify
compounds with an alternative mode of inhibition (with a bias
toward ATP competitive compounds), a focused compound
library, enhanced with ATP mimetics, was screened using the
high-throughput LdMetRS biochemical screening assay pre-
viously described.6 This library of 6708 compounds was
screened in single replicate at a concentration of 30 μM. To
assess the robustness and reproducibility of the assay and the
quality of the hit discovery campaign, various criteria were
assessed following completion of the primary screen. These data
reveal a high-quality screening campaign, with a mean robust
Z′27 of 0.82 ± 0.03 and a mean robust signal-to-background
ratio of 2.48± 0.15. Hit compounds were identified by applying
an arbitrary cutoff of 25% inhibition with 139 compounds from
the focused ATP mimetic library meeting this criteria (2.1% hit
rate) (Supporting Information Figure 1A,B). Hit compounds
were cherry picked and retested as 10-point dose−response
curves in the LdMetRS assay to determine pIC50 (−log IC50
(M)) values (pIC50 range 4.0−5.1) (Supporting Information
Figure 1C). During the subsequent chemistry assessment,
representative compounds from the key chemical series were
also tested in a counterscreen assay to determine whether there
was any interference in the assay platform. None of the
compounds tested showed inhibition in this counterscreen.
LdMetRS: Key Series SAR. Following the LdMetRS high-
throughput screen, compound 1 (Figure 1B and Table 1) was
identified as the most potent representative of a series of
compounds containing the 4,6-diamino-substituted pyrazolo-
pyrimidine core (compound series MetRS02). This compound
had moderate activity against LdMetRS (pIC50 > 5), which was
confirmed upon testing resynthesized material. A literature
search indicated that pyrazolopyrimidines are a structurally
novel class of MetRS inhibitors.
From related analogues in the library screening set, the initial
structure−activity relationship (SAR) (Table 1) suggested that
small halogens were tolerated on the 6-anilino group (i.e.,
compounds 2−6), whereas more polar substituents led to a loss
of activity (i.e., compound 7). Although little information could
be gathered from the initial screening hits regarding the SAR
around the 4-position, rapid SAR exploration of both the 4- and
6-positions was possible via sequential chlorodisplacements
from commercially available 4,6-dichloro-1-methyl-1H-
pyrazolo[3,4-d]pyrimidine as shown in Figure 2 and described
in the Supporting Information.
The initial investigation of the SAR around the 6-position of
the pyrazolopyrimidine (Table 2) focused on analogues which
maintained or reduced cLogP and also explored the effect of
increasing sp3 character. This indicated that modification at this
position was not well tolerated. Substitution of the aniline for
aliphatic groups (i.e., compounds 8−11) and methylation of the
aniline nitrogen (i.e., compound 12) led to a loss of activity, as
Figure 1. Structures of DDD806905 (MetRS01) and compound 1
(MetRS02). (A) DDD806905, a MetRS01 series inhibitor, was
previously shown to inhibit LdMetRS.6 (B) Compound 1, a
MetRS02 series inhibitor, was identified as an LdMetRS inhibitor in
the current study (with the numbering of substituted positions on the
1H-pyrazolo[3,4-d]pyrimidine included).
Table 1. Initial SAR from the 4,6-Diamine-Substituted
Pyrazolopyrimidine Series Identified from an In-House
Screen, with Modifications to the 6-Position (R1)a,b
aIn all tables, data for active compounds are from N ≥ 2 independent
replicates. bCHI = chromatographic hydrophobicity index. cLogP =
calculated log P.
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did homologation to the benzyl amine (i.e., compound 13).
Also, maintaining the para-fluoro substituent and introducing
alternative meta substituents failed to improve the activity (i.e.,
compounds 14−16).
Changes to the 4-position (Table 3) were made on the 3,4-
difluoroanilino core, and this proved more successful. While
aromatic groups were not tolerated (i.e., compound 17),
methylation of the 4-position NH led to a 5−10-fold increase
in activity (i.e., compound 18 pIC50 = 5.2 vs compound 19 pIC50
= 6.0 and compound 6 pIC50 = 4.9 vs compound 20 pIC50 = 5.6)
and methylation of the pendant hydroxyl group (i.e., compound
21) also gave an increase in potency. Saturated amino-
heterocycles (i.e., compounds 22 and 23) were tolerated, and
although a simple saturated cyclic amine (i.e., compound 24)
was inactive, an elaborated analogue (i.e., compound 25) did
retain activity possibly due to its potential to form a hydrogen
Figure 2. Generalized synthesis route to 1-methyl-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamines.
Table 2. Modifications to the 6-Position (R1)
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bondwith F339.While substitution with CH2CONHMe led to a
5-fold drop in potency (i.e., compound 26), both the equivalent
ester (i.e., compound 27) and its 1,2,4-oxadiazole isostere (i.e.,
compound 28) showed improved potency. To explore this
Table 3. Modifications to the 4-Position (R2)
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further, a series of substituted aminoesters were introduced
which led to a large improvement in activity, giving a series of
analogues with pIC50 values above 5.9 (i.e., compounds 29−32).
Despite the identification of compounds with submicromolar
potencies against LdMetRS, it was interesting to note that the
compounds returned a variety of maximum % inhibition
plateaus (Tables 1 and 3), with only a small number of
compounds showing full inhibition of the enzyme. The partial
inhibition profiles of the MetRS02 series are typified by two
compounds: compound 27 (pIC50 5.9 ± 0.2; maximum %
inhibition 92.9 ± 3.7% (N = 19)) and compound 19 (pIC50 6.0
± 0.2; maximum % inhibition 48.9 ± 0.1% (N = 5)) (Figure 3).
MetRS02 Compound Solubility. A common explanation
for partial inhibition profiles is low compound solubility.
Aqueous compound solubility was therefore assessed and, for
key representatives of the MetRS02 series, was generally found
to be low (Table 3). Supporting Information Figure 2 shows the
relationship between the maximum % inhibition plateau in the
LdMetRS dose−response curves and compound solubility,
indicating that poor solubility is themost likely driver for the low
plateaus observed in the LdMetRS assay. Despite the poor
solubility of many compounds in this series, we were able to
develop compounds with good solubility and improved potency,
resulting in full inhibition of the LdMetRS enzyme (for example,
compound 31).
LmMetRS: Binding Mode of Compound 27. To
determine the binding mode of the MetRS02 series of
compounds, a protein ligand complex was obtained by co-
crystallization of Leishmania major MetRS (LmMetRS) with
methionine and compound 27 bound (our most advanced
compound at the time of the crystallography studies)
(LmMetRS:Met:MetRS02). As this series originated from an
ATP mimetic compound library screen, we expected to see
binding in an ATP competitive manner. Surprisingly, however,
compound 27 was found to bind to a novel, allosteric ligand
binding site (Figure 4).
In contrast to the binding mode of aminoquinolone
inhibitors, which occupy both the methionine site and an
enlarged ligand-stabilized auxiliary pocket, the MetRS02 ligand
occupies a distinct site formed by the opening of the CP1
domain (Figure 4A). TheCP1 domain is not opened to the same
extent as observed for aminoquinolone (MetRS01) inhibitors,
and methionine is found to be bound to the canonical
methionine site, resulting in two distinct sites separated by the
side chain of Trp443 (Figure 4B). The binding sites of MetRS01
and MetRS02 are mutually exclusive due to the movements of
residues Tyr441, Val442, and Trp443, which form the base of
the MetRS02 cavity. As a result, these residues cannot move to
accommodate the MetRS01 chemotype, so the binding cavities
are distinct (Figure 4D).
TheMetRS02 site is created by a hinge movement of the CP1
domain from residues Lys327 and Glu372, resulting in an
opening of 15°. The overall secondary structure of the CP1
domain is retained with fewer structural changes than observed
for the conformational changes stabilized by the amino-
quinolone inhibitors. The KISKS loop retains an open
conformation due to the absence of ligands within the ATP
binding site (Figure 4C). For productive catalysis to occur, both
the CP1 domain and KISKS motif have to fully engage with
substrate ATP; it is proposed that molecules from the MetRS02
series act as enzyme inhibitors by blocking CP1 domain
movement, preventing the enzyme from forming the required
catalytic conformation.
The MetRS02 binding site is largely hydrophobic in nature
(Figure 4B), formed by side chains of Tyr328, Glu337, Ser338,
Phe339, Phe414, Leu416, Ser417, Ile418, Tyr441, Trp443,
Leu444, Leu447, Phe490, Tyr494, and Phe498. The difluor-
obenzyl group binds in a hydrophobic pocket formed by the side
chains of Leu416, Ile418, Tyr441, Trp443, Leu444, Leu447,
Phe490, Tyr494, and Phe498, while the pyrazolopyrimidine
moiety stacks among Phe339, Phe414, and Tyr328.
Two H-bonds are formed between the pyrazolopyrimidine
core and the backbone of Ser417; the one N lone pair interacts
with the backbone NH, and the two amino NH groups interact
with the backbone carbonyl. The pendant methyl acetate group
carbonyl H-bonds to the backbone NH of Phe339 and enters a
polar channel toward the active site.
Figure 3. LdMetRS compound 27 and Compound 19 pIC50 determinations. (A) Compound 27 and (B) compound 19 inhibit LdMetRS with pIC50
values of 5.9 ± 0.2 (N = 19 independent replicates) and 6.0 ± 0.2 (N = 5 independent replicates), respectively, and with maximum % inhibition
plateaus of 92.9 ± 3.7 and 48.9 ± 0.1, respectively, when screened using final substrate conditions of 50 μM methionine and 100 μM ATP.
Representative dose−response curves are presented, with data points representing the mean % inhibition ± SD (n = 3 technical replicates).
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Figure 4. LmMetRS compound 27 binding mode. (A) Binding mode of compound 27 (MetRS02) and methionine bound to LmMetRS. Ligands are
shown in a stick representation with C atoms colored gold. (B) Interactions formed between MetRS02 and LmMetRS. H-bonds are shown as dashed
lines, and key residues are labeled for clarity. (C) MetRS-ligand-stabilized conformational changes. LmMetRS:MetAdn (PDB 3KFL), gray cartoon;
LmMetRS:Met:MetRS02, blue cartoon; and TbMetRS:Met:MetRS01 (PDB 5NFH), green cartoon showing the movement of CP1 and KISKS
domains. (D) Comparison of ligand binding sites. LmMetRS:Met:MetRS02 C atoms, green; and TbMetRS:Met:MetRS01 (PDB 5NFH) C atoms,
magenta.
Figure 5. LdMetRS compound 27 mode of inhibition. Rate versus (A) methionine or (B) ATP concentration plots for LdMetRS in the presence of
various concentrations of compound 27. Data sets were globally fitted to the partial, cooperative, noncompetitive inhibition model (eq 7) with fit
parameters reported in Table 4. (See also Supporting Information Figure 4, which highlights the quality of the data fit for the lower substrate
concentrations tested.) For all data points, n = 1. In both panels, compound concentrations are 100 μM(closed hexagons), 50 μM(open stars), 25 μM
(closed stars), 12.5 μM(open diamonds), 6.25 μM(closed diamonds), 3.13 μM(open triangles), 1.56 μM(closed triangles), 0.78 μM(open squares),
0.39 μM (closed squares), 0.2 μM (open circles), and 0 μM (closed circles).
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The observed binding mode of 27 to LmMetRS provides a
structural rationale for the SAR derived for the MetRS02 series
in general (Tables 1−3). The hydrophobic nature of the
difluorobenzyl pocket explains the distinct preference for
aromatic substituents at the 6-position of the pyrazolo-
pyrimidine core with a potency loss for molecules with aliphatic
or polar moieties. The importance of the H-bond formed by the
aniline NH with the protein backbone is highlighted by the loss
of potency whenmethylated. The observed SAR for substitution
at the 4-position shows a preference for an H-bond acceptor
group as exemplified by the interaction between the ester
carbonyl of 27 and the NH backbone of Phe339.
LdMetRS: MetRS02 Series Mode of Inhibition. In
addition to the crystallographic information, enzymatic studies
were also carried out on compounds from theMetRS02 series to
determine their mode of inhibition. Preliminary data generated
with compound 27 revealed no IC50 shifts when the methionine
and ATP concentrations were increased from 50 μMeach to 500
μM (Supporting Information Figure 3), suggesting that this
inhibitor is not competitive with either substrate.
Subsequent full mode of inhibition studies with compounds
from the MetRS02 series were more challenging due to the
partial inhibition profiles of some compounds resulting in poor
global fits to the standard competitive, uncompetitive, and
noncompetitive inhibitionmodels (eqs 3, 4, and 5, respectively).
In addition, during the enzymatic characterization of methio-
nine binding to LdMetRS, a Hill slope of <1 was obtained (and
was hypothesized to be due to conformational selection).6 This
low Hill slope is also not factored into the standard inhibition
models described (eqs 3−5). New models with additional
parameters to account for the partial inhibition and low
methionine Hill slope were therefore required (eqs 6 and 7).
Table 4. Kinetic Parameters Describing Compound 27 and Compound 19 Modes of Inhibitiona
compound enzyme substrate Ki (μM)
β (fraction of activity
remaining)
h (inhibitor Hill
slope)
Vmax (μM Pi
formed/min) Ks(μM)
n (substrate Hill
slope)
27 LdMetRS methionine 2.06 ± 0.04 0.060 ± 0.005 1.05 ± 0.02 0.388 ± 0.009 327 ± 35 0.50 ± 0.01
ATP 1.58 ± 0.04 0.027 ± 0.005 1.10 ± 0.02 0.324 ± 0.004 21.1 ± 0.6 1.07 ± 0.02b
TcMetRS methionine 10.8 ± 0.7 0.65 ± 0.01 1.48 ± 0.11 0.429 ± 0.016 1340 ± 237 0.42 ± 0.01
ATP 11.3 ± 1.2 0.48 ± 0.02 1.27 ± 0.14 0.287 ± 0.006 40.5 ± 2.0 1.07 ± 0.03b
19 LdMetRS methionine 1.22 ± 0.06 0.57 ± 0.01 1.65 ± 0.11 0.359 ± 0.009 313 ± 35 0.53 ± 0.02
ATP 1.21 ± 0.06 0.55 ± 0.01 1.75 ± 0.12 0.292 ± 0.004 21.0 ± 0.74 1.03 ± 0.03b
TcMetRS methionine inactive N/A N/A N/A N/A N/A
ATP inactive N/A N/A N/A N/A N/A
aAll data fits are to the partial, cooperative, noncompetitive mode of the inhibition model (eq 7). Data are presented as the parameter ± SE of fit to
represent the goodness of fit of the data to eq 7. bAs expected, the Hill value for ATP is close to 1. (No cooperativity is seen with this substrate.)
Fixing this parameter to 1 for the ATP mode of inhibition experiments resulted in fit parameters in close agreement with those reported in the table
above.
Figure 6. TcMetRS assay development summary. (A) Methionine Km
app determination in the presence of a saturating concentration of 350 μMATP.
Representative data are shown as the mean rate± SD (n = 4 technical replicates) and were fitted to eq 1. (B) ATP Km
app determination in the presence
of a saturating concentration of 3 mMmethionine. Representative data are shown as the mean rate± SD (n = 4 technical replicates) and were fitted to
eq 2. (C) Assay linearity with respect to enzyme concentration. Data are shown as the mean rate± SD (n = 3 technical replicates). (D) Assay linearity
with respect to time under the final assay screening conditions of 50 μMmethionine and 100 μM ATP either with (closed circles) or without (open
circles) the 80 nM TcMetRS enzyme. Data are shown as mean A650± SD (n = 3 technical replicates). (E) Representative DDD806905 dose−response
curve generated under final screening substrate conditions of 50 μMmethionine and 100 μMATP. Data are presented as the mean % inhibition± SD
(n = 3 technical replicates).
ACS Infectious Diseases pubs.acs.org/journal/aidcbc Article
https://dx.doi.org/10.1021/acsinfecdis.9b00453
ACS Infect. Dis. 2020, 6, 1044−1057
1050
Using these modified equations, the mode of inhibition of
compound 27 was carried out by testing LdMetRS enzyme
activity under varying substrate concentrations at various
inhibitor concentrations (Figure 5). The cooperative, non-
competitive, partial inhibition model (eq 7) was confirmed as
the best fit (using F-test analyses), with a noncompetitive mode
of inhibition consistent with binding in an allosteric binding
pocket. The returned fit parameters are shown in Table 4 and are
presented with the standard error (SE) of the fit to eq 7. In most
cases, the SE is <10% of the parameter value highlighting the
excellent fit observed, with Supporting Information Figure 4 also
demonstrating the high-quality fit even at low substrate
concentrations.
Mode of inhibition studies for a second available compound
from this series (compound 19) confirmed that the non-
competitive mode of inhibition model (eq 7) was the best fit to
the data (Supporting Information Figure 5 and Table 4).
TcMetRS: Assay Development. The novel allosteric
binding pocket and the noncompetitive inhibition profile seen
with the MetRS02 series of compounds were unexpected given
that this hit series came from a screen of a compound library
enriched with ATP mimetics. As expected from the high degree
of active site homology between the kinetoplastid MetRS
enzymes, the previously described orthosteric MetRS01 series
shows MetRS inhibition across kinetoplastid species. However,
as the newly identified LdMetRS inhibitors target an allosteric
binding pocket not previously described, we were interested in
investigating the activity of the MetRS02 compound series in
another kinetoplastid MetRS enzyme. As Chagas disease is a key
disease focus for our organization, MetRS from Trypanosoma
cruzi was selected for further study.
A BIOMOL Green biochemical assay, comparable to that
developed for LdMetRS, was also developed for TcMetRS, with
Michaelis constants for the methionine and ATP substrates
determined (Figure 6A,B) and assay linearity with respect to
enzyme concentration and time assessed (Figure 6C,D).
The TcMetRS apparent Michaelis constants for methionine
and ATPwere determined to be 212 μM(95%CI 139−324 μM;
N = 3 independent replicates) (with a Hill slope of 0.63 ± 0.16)
and 63 μM(95%CI 31−125 μM;N = 3 independent replicates)
(with a substrate inhibition constant of 2080 μM (95% CI
1160−3740 μM)), respectively. These Kmapp values are highly
comparable to those previously determined for the LdMetRS
enzyme (173 and 37 μM for methionine and ATP
respectively).6 In addition, the subunity Hill slope observed
withmethionine and the substrate inhibition observed with ATP
match that seen in the LdMetRS assay, suggesting that,
kinetically, the two enzymes are very similar. For screening
purposes, the TcMetRS assay was configured to match the
LdMetRS assay, with subsaturating concentrations of 50 μM
methionine and 100 μM ATP selected to ensure that the assay
was not biased toward a particular inhibition modality. Using
these assay conditions, the TcMetRS assay was validated using
previously described LdMetRS inhibitor DDD806905. This
MetRS01 compound was shown to inhibit theTcMetRS enzyme
with a pIC50 of 7.4 ± 0.1 (mean ± SD; N = 16 independent
replicates (IC50 38 nM)) (Figure 6E), which is comparable to
the pIC50 of 7.0 (IC50 94 nM) described for LdMetRS.
6
However, on the basis of the enzyme concentration used in the
biochemical assay (80 nM TcMetRS) and the high Hill slopes
determined in the IC50 fits (Hill slopes = 2.6 ± 0.3), it is highly
likely that the tight binding limit of the TcMetRS assay has been
reached and the actual IC50 of DDD806905 is lower than
recorded.
LdMetRS versus TcMetRS Inhibitor Correlations.
Interestingly, screening key compounds from the MetRS02
series revealed that most compounds were inactive against
TcMetRS (defined as no compound concentration tested
showing >50% inhibition, i.e., IC50 > 100 μM; pIC50 < 4.0)
(Table 3). Further investigation of a larger panel of 201
compounds from this chemical series (available from an
unrelated in-house project) shows a wide range of potencies
against LdMetRS (pIC50 range 4.0−6.7) and confirms the much
lower potency against TcMetRS (Figure 7). On the basis of the
data for the more soluble and potent compounds (compounds
29−31), compounds in this series are approximately 10-fold less
potent against the TcMetRS enzyme than against LdMetRS.
While representative compound 27 returned a pIC50 < 4 in
our TcMetRS screening assay, it still showed some level of
inhibition of the TcMetRS enzyme, with a maximum %
inhibition of 44.2 ± 6.5% (N = 19 independent replicates). It
was therefore feasible to perform TcMetRS mode inhibition
studies with this compound. These studies, carried out as
previously described for LdMetRS, confirm a best fit to the same
partial, cooperative, noncompetitive inhibition model (eq 7;
Supporting Information Figure 6 and Table 4). These data show
that although compound 27 inhibits TcMetRS via the same
mechanism as for LdMetRS, the Ki of this compound is ∼5−7-
fold less against the TcMetRS enzyme than against LdMetRS.
TcMetRS: Homology Model. To account for the different
potencies observed between the LdMetRS and TcMetRS
enzymes, TcMetRS (Uniprot: Q4D6H2) was modeled on the
basis of the in-house LmMetRS X-ray structure cocrystallized
with compound 27 (Figure 8). The sequences were 67%
identical (with 81% of residue changes conservative) (Support-
ing Information Figure 7). Two residues that have direct contact
with the ligand in the crystal structure show sequence differences
between LmMetRS and TcMetRS. Ile418 forms nonpolar
contacts with the ligand’s difluorophenyl group; this interaction
is reproduced by the corresponding valine residue in the
TcMetRS model. Phe414 forms a parallel-displaced π-stacking
interaction with the pyrazolopyrimidine core in the LdMetRS
structure. Phe414 corresponds to an Asn in TcMetRS with no
accessible side-chain orientations for π-stacking with the
pyrazolopyrimidine in our model. These sequence differences
Figure 7. LdMetRS versus TcMetRS potency correlation. Correlation
between mean LdMetRS pIC50 and mean TcMetRS pIC50. Dashed line
is a line of equipotence. Data points represent the mean pIC50 (N = 2
independent replicates).
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may be an important contributor to the lower potency of the
series for TcMetRS compared to LdMetRS.
Furthermore, Phe498 forms nonpolar contacts with the
difluorophenyl group of the ligand in the crystal structure. While
this is a conserved residue between the Leishmania and T. cruzi
MetRS enzymes, it can adopt a distinct, flipped side-chain
conformation in TcMetRS and consequently may lose its
contacts with the ligand. Flipping of the Phe498 side chain may
be possible due to sequence differences in this region, namely,
Phe448 (Lm) corresponding to a serine and Ile313 (Lm)
corresponding to a leucine in TcMetRS.
■ DISCUSSION
MetRS is a promising drug target for many disease-relevant
organisms due to its central role in protein synthesis. Extensive
work on this enzyme for kinetoplastid parasites T. brucei and L.
donovani has focused on compounds that bind to the active site
and compete with methionine, including an aminoquinolone
(MetRS01) series of compounds. Despite the concerted efforts
of several groups, these compounds have not progressed to late-
stage drug discovery due to developability challenges (e.g.,
hERG liability, poor in vivo distribution, etc.). To overcome
these issues there is a pressing need to identify new chemotypes
that inhibit this enzyme.
In the present study, a new series of 4,6-diamino pyrazolo-
pyrimidine (MetRS02) LdMetRS inhibitors were identified
following a high-throughput screen against a focused compound
library enhanced with ATP mimetics. Due to the nature of the
compound library screened, any hits identified were expected to
compete with ATP for binding. Surprisingly, structural and
enzymatic studies revealed that representative members of this
compound series bind to an allosteric site not previously
described and display noncompetitive inhibition where the
inhibitor binds to both the free enzyme and enzyme substrate
complex with equal affinity.
The identification of a novel allosteric binding pocket in the L.
donovani and T. cruziMetRS enzymes offers a new strategy from
a drug discovery perspective, particularly in view of the above-
mentioned challenges in development faced by existing
orthosteric inhibitors. Targeting an allosteric pocket is also
likely to provide new ways of achieving selectivity over human
orthologues, a particular challenge for MetRS given the high
degree of active site homology between kinetoplastids and
human enzymes. In addition, compounds displaying non-
competitive modes of inhibition are advantageous as, unlike
active site inhibitors, they are not affected by high concen-
trations of substrates in the cell. As such, the identification of the
MetRS02 compound series and binding pocket provides an
opportunity to explore these allosteric inhibitors.
Within theMetRS02 series, many compounds did not achieve
full inhibition of the enzyme. The level of inhibition correlates
with aqueous solubility, indicating that the primary driver for the
low plateaus is likely to be poor compound solubility rather than
the enzyme−substrate−inhibitor complex undergoing catalysis
at a reduced rate. However, in some cases, compounds with
equally low solubility did achieve nearly full inhibition (e.g., 27),
whereas others (e.g., 19) did not (Table 3). The potency and
partial inhibition of these compounds correlate well with the Ki
values and β-factors in Table 4, so a partial inhibitionmechanism
cannot be completely excluded at present. Also, it is important to
point out that solubility and potency measurements are
performed under different conditions (i.e., buffer composition,
pH, and timing). The biochemical assay is carried out over 2 h
whereas solubility is measured after 24 h to ensure that steady-
state equilibrium is achieved, thus temporary supersaturation
may result in compound concentrations above the reported
solubility limit in the biochemical assay. Importantly, when good
potency and solubility are combined, full inhibition of both the
Leishmania and T. cruzi enzymes is observed (compound 31).
Across the series, TcMetRS potency was consistently lower
than for the Leishmania enzyme, with many LdMetRS active
compounds inactive against the T. cruzi enzyme. The data for
the most potent and soluble compounds indicates that the series
is approximately 10-fold less potent against the T. cruzi enzyme.
The homology model generated for TcMetRS shows that some
key residues involved in MetRS02 compound binding differ
from those in the Leishmania enzyme. The Phe414 (Lm)/Asn
(Tc) difference is likely a key driver for the lower effect on the T.
cruzi enzyme. Phe414 makes an important contribution to
compound binding through aromatic π-stacking with the
Figure 8. TcMetRS homology model. Sequence differences between LmMetRS and TcMetRS. Superposition of TcMetRS homology model on the
LmMetRS:Met:MetRS02 crystal structure (main chain, ribbon; side chains, gray sticks) withTcMetRS sequence differences shown as sticks (C atoms,
light blue) and labeled. Sequence alignment of LmMetRS and TcMetRS. Residues that form the MetRS02 binding site are highlighted by red upward
arrows. F414N is highlighted with a black arrow, and back-pocket residues are highlighted with blue arrows.
ACS Infectious Diseases pubs.acs.org/journal/aidcbc Article
https://dx.doi.org/10.1021/acsinfecdis.9b00453
ACS Infect. Dis. 2020, 6, 1044−1057
1052
pyrazolopyrimidine core which is not reproduced by the Asn
residue in the T. cruzi enzyme. Another important difference is
in the orientation of Phe498, which in the Leishmania structure
interacts with the difluorophenyl moiety of the MetRS02
compounds. This residue is conserved in the T. cruzi enzyme,
but our homology model predicts a different orientation for this
residue, potentially precluding its contribution to ligand binding.
Future chimera studies are needed to support these hypotheses.
Initial testing of selected compounds in Leishmania and T.
cruzi cell-based assays showed no or minimal inhibition of
parasite viability. At this stage in the development of this series,
this is not surprising, as compounds are likely not potent enough
to show a cellular effect and other factors such as permeability
and stability may not be optimal yet. This work provides new,
validated hits against LdMetRS, but further improvement of the
properties of the series, an understanding of the potential for
selectivity over the human orthologues, and proof of concept in
cell-based parasite assays are required to understand the
usefulness of this new allosteric binding site in the MetRS
enzyme for drug discovery purposes.
■ CONCLUSIONS
Wehave identified a novel strategy to target the essential enzyme
methionyl-tRNA synthetase in kinetoplastid parasites through a
newly identified allosteric pocket adjacent to the active site.
Drug discovery efforts by several groups targeting the orthosteric
binding site have not yielded candidates for late-stage drug
discovery to date due to issues relating to poor in vivo
distribution and hERG liability. Thus, the identification of a
novel binding site and a new chemotype offers a welcome
alternative to targeting this enzyme for neglected tropical
diseases leishmaniasis and Chagas disease.
■ MATERIALS AND METHODS
LdMetRS Protein Expression and Purification. An E. coli
codon optimized (Genscript) version of the full-length
LdMetRS gene (TriTrypDB ID LdBPK_210890) was cloned
into the pET15b TEV vector using Nde1 and Xho1 restriction
sites. The vector had been previously modified to include a His
tag and a TEV cleavage site at the N terminus. The plasmid was
transformed into BL21 DE3 E. coli cells. One liter cultures were
grown in autoinduction + AMP media28 at 37 °C and 200 rpm
until the OD600 reached 0.8. The temperature was then
reduced to 22 °C at 200 rpm overnight. Cells were harvested by
centrifugation at 3000g for 20 min and stored at −20 °C. The
pellets were resuspended in 150 mL of 20 mMHEPES, 500 mM
NaCl, 5% glycerol, 1 mM TCEP, 10 μM ZnCl2, and 20 mM
imidazole pH 7.0 (buffer A) supplemented with DNase I (400
U/mL) and protease inhibitor tablets (1 per 50 mL of lysis
buffer). The cells were lysed using the Continuous Flow Cell
Disrupter (Constant Systems) at 30 kilo-pound per square inch.
The lysate was centrifuged at 40 000g for 20 min, and the
supernatant was then filtered (0.2 μm). The sample was loaded
onto a 5 mL HiTrap His column (GE Healthcare) equilibrated
with buffer A on an AKTA Purifier (GE). The column was then
washed with 10 column volumes of buffer A. A step gradient of
5% buffer B (A + 500 mM imidazole) was used to remove
histidine-rich protein contaminants. A gradient of 5 to 50% B
over 20 column volumes was used to elute the LdMetRS. The
protein was then concentrated to 11 mL for gel filtration. Gel
filtration was carried out on a Superdex 200 26/60 prep-grade
column (GE) in 20 mM HEPES, 500 mM NaCl, 5% glycerol, 1
mM TCEP, and 10 μM ZnCl2 at pH 7.0. Glycerol (10%) was
added for storage at −80 °C.
LmMetRS Protein Expression and Purification.
LmMetRS (206−747) was expressed and purified as described
previously.26 Briefly, an E. coli codon optimized sequence
corresponding to residues 206−747 of L. major MetRS
(LmjF21.0810) was cloned into a pET-15-derived vector
encoding an N-terminal 6xHis tag followed by a TEV cleavage
site. Protein was purified by Ni-NTA affinity chromatography
followed by size exclusion chromatography using 20 mM
HEPES, 500 mM NaCl, 5% glycerol, 1 mM TCEP, and 10 μM
ZnCl2 at pH 7.0 as the buffer. Protein was concentrated to 24
mg/mL for crystallization experiments.
TcMetRS Protein Expression and Purification. The gene
encoding full-length T. cruzi MetRS (TriTrypDB ID TcSil-
vio_007991) was synthesized and codon optimized for
baculovirus by Genscript and cloned into pFASTBac with an
N-terminal His tag and a TEV cleavage site.
The plasmid was transformed into DH10 α-cells to create the
bacmid. The bacmid was then transfected into Sf9 cells in a six-
well plate at 1.5 × 106 cells/well using Insect Gene Juice
(Merck). The plate was incubated for 7 days at 26.5 °C. The
transfection was harvested and labeled P0. The virus was then
amplified sequentially to give the P1 and P2 viruses. For large-
scale expression, 2× 500mL Sf9 cells at 1.5× 106 cells/mL were
infected with 3% P2 virus and incubated at 26.5 °C and 125 rpm
for 72 h. Following harvesting at 1000g for 20 min, the cell pellet
was processed immediately. For larger-scale production,
expression (10L) was carried out using an Appliflex system
(Applikon Biotechnology). The pellet was resuspended in 15
mL of lysis buffer per 5 g of pellet weight (25 mM HEPES pH
7.5/500 mM NaCl/2 mM DTT/5% glycerol/10 mM L-
methionine/20 mM imidazole/400 U/mL DNase I/cOmplete
Protease Inhibitor tablets (1 per 50 mL of lysis buffer). The
suspension was then passed through a continuous flow cell
disrupter (Constant Systems) at 30 kilo-pound per square inch.
The sample was then centrifuged at 37 500g for 30min, followed
by filtration through a 0.22 μm filter.
A 5 mL His Trap Ni HP (GE Healthcare) was equilibrated
with buffer A (25 mM HEPES pH 7.5/500 mM NaCl/2 mM
DTT/5% glycerol/10 mM L-methionine/20 mM imidazole) on
an AKTA purifier system (GE Healthcare). The sample was
loaded using a sample pump at 5 mL/min. The column was then
washed with 10 column volumes of buffer A. The column was
then washed with 5% buffer B (25 mMHEPES pH 7.5/500 mM
NaCl/2 mM DTT/5% glycerol/10 mM L-methionine/500 mM
imidazole)/95% buffer A to remove contaminating histidine-
rich proteins. A gradient of 5−50% buffer B was then used to
elute the protein.
The protein was dialyzed against buffer C (25mMHEPES pH
7.5/250 mM NaCl/1 mM DTT/5% glycerol/10 mM L-
methionine). An XK26/60 Superdex 200 column was
equilibrated with buffer C. The protein sample was concentrated
to 11 mL using a 30 kDa cutoff Vivaspin spin concentrator
(Sartorius), passed through a 0.22 μm filter, and loaded onto the
column using a 10 mL loop at 1 mL/min. The protein, which
eluted as a monomer (column calibrated with BioRAD
standards), was then concentrated to 5 mg/mL. The protein
was shown to be almost 100% pure by SDS-PAGE densitometry
(BioRAD Imager), and the identity of the protein was confirmed
by mass spectrometry.
Compound Solubility. Solubility was assessed using a
filtration-based method. Test compounds were dissolved in
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DMSO to give 10 mM solutions. Five microliters of the 10 mM
solution was added to 195 μL of phosphate-buffered saline at pH
7.4 and mixed for 24 h (rotary mixing, 900 rpm, 25 °C)
excluding light. After mixing, the samples were filtered to remove
any undissolved material using a Millipore Multiscreen HTS
filter. The filtrate was analyzed for dissolved drug compounds
using UHPLC.
CHI LogD and cLogP Measurements. CHI LogD
measurements were performed as described elsewhere.29
cLogP measurements were calculated using StarDrop (Opti-
brium).
LmMetRS:MetRS02 Protein Crystallography. Protein:li-
gand complexes were obtained by cocrystallization. For
crystallization, LmMetRS was prepared at 24 mg/mL in 20
mM HEPES, 500 mM NaCl, 0.01 mM ZnCl2, 1 mM TCEP
supplemented with 1 mM Mg-ATP, and 10 mM L-methionine.
The ligand was solubilized to 200 mM in DMSO and added to
the protein solution to a final concentration of 6 mM.
Crystallization was carried out by vapor diffusion using the
sitting drop method. A grid screen consisting of 23−28% PEG
3350 and 0.2 M potassium formate at pH 7.0−7.5 was prepared
in 96-well MRC 2 drop plates with a reservoir volume of 50 μL.
Drops were prepared by mixing 1 μL of protein with 1 μL of
reservoir solution before plates were sealed and incubated at 18
°C. After 72 h, large crystals were obtained in many of the
crystallization wells.
Crystals were cryoprotected in mother liquor plus 20%
glycerol and flash frozen in liquid nitrogen prior to data
measurement at Diamond Light Source beamline I03. Crystals
were found to be isomorphous with the reported LmMetRS
structure belonging to the P212121 space group with unit cell
dimensions of a = 54.17 Å, b = 100.80 Å, and c = 132.0 Å.
Diffraction data were measured to 2.0 Å resolution, integrated
with XDS30 and reduced using Aimless.31 The structure was
phased by molecular replacement as implemented in MOL-
REP32 using the LmMetRS:MetAMP complex (PDB 3KFL) as a
search model. Refinement was carried out using Refmac5,33
ligand topology files created with jligand34 and manual model
alteration using COOT.35 Data measurement and refinement
statistics are shown in Supporting Information Table 1.
Coordinate files and associated experimental data have been
deposited in the Protein Data Bank (PDB) with accession code
6SWX.
TcMetRS Homology Model. The TcMetRS sequence
(UniProt ID: Q4D6H2) was homology modeled on the basis
of the LmMetRS crystal structure with compound 27 bound
using Prime Homology Modeling tools implemented in
Schrödinger software (Schrödinger, LLC). Sequences were
aligned using Prime ClustalW, and the model was built by
applying the energy-based method, including the cocrystallized
ligand. Nontemplate loops were refined in Prime (as
recommended). The final model was refined in the Protein
Preparation Wizard suite, and restrained energy minimization
was applied to the default root-mean-square deviation of 0.3 Å.
TcMetRS Assay Development and Kinetic Parameter
Determinations. The activity of the TcMetRS enzyme was
determined by monitoring levels of pyrophosphate released
during the first step of the enzymatic reaction. The
pyrophosphate formed was converted to two inorganic
phosphate molecules using a pyrophosphatase enzyme, and
levels of the resulting phosphate molecules were measured using
the BIOMOL Green reagent (Enzo Life Sciences).
TcMetRS assays were carried out using 384-well, clear, flat-
bottomed plates (Greiner) at room temperature (∼23 °C) in 50
μL reaction volumes of assay buffer (30 mM Tris, pH 8.0, 140
mM NaCl, 30 mM KCl, 40 mM MgCl2, 0.01% (v/v) Brij-35, 1
mM DTT) plus 1 U/mL pyrophosphatase and varying
concentrations of enzyme and substrates. Enzyme linearity
was assessed in a 90 min end-point assay with varying TcMetRS
concentrations (0−320 nM), 50 μM L-methionine, and 100 μM
ATP. Reactions were stopped with the addition of 50 μL of
BIOMOL Green reagent, with the signal allowed to develop for
30 min before the absorbance of each well was read at 650 nm
(A650) using a PheraStar plate reader (BMG).
Apparent Michaelis constants (Km
app) for the L-methionine
and ATP substrates were determined in end-point assays using
the above buffer conditions and 80 nM recombinant TcMetRS.
To determine L-methionine Km
app, various L-methionine
concentrations were tested in the presence of a fixed, saturating
concentration of ATP (350 μM). To determine the ATP Km
app,
various ATP concentrations were tested in the presence of a
fixed, saturating concentration of L-methionine (3 mM).
Following a 90 min reaction at room temperature, assays were
stopped with the addition of 50 μL of BIOMOLGreen, and A650
was read as previously described. Using a BIOMOL Green
phosphate standard curve, A650 data were converted to reaction
rates and rate versus substrate concentration data were fitted to
modified Michaelis−Menten equations using GraFit v6.0
(Erithacus Software). Equation 1 was used to determine the L-
methionine Km
app, and eq 2 was used to determine the ATP
Km
app.
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v is velocity, Vmax is the maximum velocity, [S] is the substrate
concentration, Km is the Michaelis constant, n is the Hill slope,
and Ki
s is the substrate inhibition constant.
LdMetRS and TcMetRS Compound Screening. All
screening assays were performed in 384-well, clear, flat-bottom
plates (Greiner) at room temperature (∼23 °C) in 50 μL
reaction volumes containing assay buffer plus 1 U/mL
pyrophosphatase, 50 μM L-methionine, 100 μM ATP, and
either 80 nM TcMetRS or 50 nM LdMetRS.
Single-point LdMetRS inhibition assays were carried out by
dispensing test compound (or DMSO to control wells) into
assay wells using an ECHO 550 acoustic dispenser (Labcyte).
Assays were then performed by adding 25 μL of assay buffer with
enzyme to assay plates (with assay buffer added only to “no
enzyme” control wells) before the reaction was initiated with the
addition of a 25 μL mixture containing L-methionine, ATP, and
pyrophosphatase to all wells. Following a 120 min reaction at
room temperature, the assay was stopped with the addition of 50
μL of BIOMOLGreen. The BIOMOLGreen signal was allowed
to develop for 30 min before the absorbance of each well was
read at 650 nm using an EnVision multilabel plate reader
(PerkinElmer Life Sciences) or a PheraStar plate reader (BMG).
All liquid dispensing steps were carried out using a Thermo
Scientific WellMate dispenser (Matrix).
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ActivityBase from IDBS (version 8.0.5.4) was used for data
processing and analysis, with percentage inhibition values
determined relative to 100% inhibition and 0% inhibition
control wells on each plate.
To generate IC50 data for hit compounds in the LdMetRS or
TcMetRS assays, 10-point inhibitor dose response curves were
prepared in 384-well assay plates using an ECHO 550 acoustic
dispenser (Labcyte). Following preparation of the inhibitor
curves, assays were carried out as described above using either 50
nM LdMetRS or 80 nM TcMetRS.
ActivityBase from IDBS was again used for data processing
and analysis. All IC50 curve fitting was undertaken using
ActivityBase XE (version 7.7.1) from IDBS. A four-parameter
logistic dose−response curve was utilized (XLfit model 203)
with prefit used for all four parameters.
MetRS Counterscreen. Counterscreen assays, to identify
any compounds inhibiting the pyrophosphatase enzyme or
interfering with the BIOMOLGreen assay readout, were carried
out. As described above, 10-point inhibitor curves were prepared
in 384-well plates using an ECHO 550 acoustic dispenser
(Labcyte). Assays were performed in 50 μL reaction volumes
containing assay buffer plus 1 U/mL pyrophosphatase and 1.2
μM pyrophosphate. Pyrophosphate was excluded from 100%
effect control wells.
Following a 120 min incubation at room temperature (∼23
°C), the detection of phosphate levels using the BIOMOL
Green reagent was carried out as previously described. All liquid
dispensing steps were carried out using a Thermo Scientific
WellMate dispenser (Matrix).
Data processing and analysis were performed using
ActivityBase from IDBS as described above.
LdMetRS and TcMetRS Mode of Inhibition Studies. To
establish the mode of inhibition of compounds 19 and 27, data
sets (generated using the BIOMOL Green assay platform
previously described) were collected by varying both the
inhibitor and substrate concentrations. Using GraFit v6.0
(Erithacus Software), each data set was globally fitted to
standard competitive, uncompetitive, and noncompetitive
inhibition models (eqs 3−5).
Equation 3 (competitive inhibition model):
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On the basis of poor data fits to the above models, partial
inhibition and cooperativity parameters were introduced into
the uncompetitive and noncompetitive models as previously
described by Skovpen et al.36,37 Mode of inhibition data were
globally fitted to these modified equations (eqs 6 and 7).
Equation 6 (cooperative, uncompetitive, partial inhibition
model):
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Equation 7 (cooperative, noncompetitive, partial inhibition
model):
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v is the velocity, Vmax is the maximum velocity, [S] is the
substrate concentration, [I] is the inhibitor concentration, Ki is
the inhibitor constant,Ks is the substrate dissociation constant, n
is the substrate Hill slope, h is the inhibitor Hill slope, and β is
the proportionality constant (fraction of activity remaining
when the enzyme is fully saturated with inhibitor).
If more than one model appeared possible, then data were
fitted to both and examined for significance using the F-test
function in GraFit.
Chemistry. See the Supporting Information.
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